Daniel R. Karlin, MD, MA

Dan joined Definium as Chief Medical Officer in February 2021 following Definium’s acquisition of HealthMode, a company he co-founded and led as CEO.

Prior to HealthMode, he built and led clinical, informatics, and regulatory strategy for Pfizer’s Digital Medicine and Innovation Research Lab. He previously served as Global Clinical Lead for psychiatry clinical compounds at Pfizer. He was co-founder and Chief Medical Officer at Column Health, a leading technology-enabled psychiatry and addiction practice. He is a strategic advisor to several pharmaceutical, biotech, and health technology companies, and a founding Advisor to the Digital Biomarkers Journal, co-founder and Board Chair of the Digital Medicine Society (DiMe), and was on the committee for Leadership for Digital Drug Development Tools at Critical Path Alzheimer’s Disease, MJFF, and Mental Health IT at the APA.

Dan is Board Certified in Psychiatry, Addiction Medicine, and Clinical Informatics. He is a Fellow of the American Psychiatric Association (APA) and the American Society of Addiction Medicine (ASAM). He is an Assistant Professor of Psychiatry at Tufts University School of Medicine. He graduated with degrees in Neuroscience and Behavior (BA), and Clinical Informatics (MA), Columbia University; Medicine (MD), University of Colorado School of Medicine.